Evidence map›Paper›PMID 42359075›Full record

ArticleFrontiers in medicine2026

Comparison of Child-Pugh and MELD scores in predicting survival of hepatocellular carcinoma patients with splenomegaly undergoing TACE: a real-world study.

Lu Xu, Bo Jiang, Yicheng Ma, Jianhua Pan, Ming Liang, Qianqian Du, Haotian Wu, Zhiheng Cheng, Dong Lu

Abstract read
In one paragraph

Article in Frontiers in medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Lu XuInvasive Technology Department, Second Hospital of Anhui Medical University, Hefei, China.
Bo JiangInvasive Technology Department, Second Hospital of Anhui Medical University, Hefei, China.
Yicheng MaInvasive Technology Department, Second Hospital of Anhui Medical University, Hefei, China.
Jianhua PanInvasive Technology Department, Second Hospital of Anhui Medical University, Hefei, China.
Ming LiangInvasive Technology Department, Second Hospital of Anhui Medical University, Hefei, China.
Qianqian DuInvasive Technology Department, Second Hospital of Anhui Medical University, Hefei, China.
Haotian WuInvasive Technology Department, Second Hospital of Anhui Medical University, Hefei, China.
Zhiheng ChengInvasive Technology Department, Second Hospital of Anhui Medical University, Hefei, China.
Dong LuInvasive Technology Department, Second Hospital of Anhui Medical University, Hefei, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Objective: This study aims to compare the predictive value of Child-Pugh and MELD scores for the survival rate of HCC patients with splenomegaly who received TACE. Methods: From January 2018 to January 2025, 306 patients with splenomegaly and HCC who underwent TACE treatment at a tertiary hospital were included in the study. Patients were divided into groups A ( Results: The comparison analysis of baseline characteristics showed that there were statistically significant differences in age, maximum tumor diameter, proportion of multifocal tumors, spleen length, total bilirubin, albumin, international normalized ratio (INR), creatinine, red blood cell distribution width (RDW), platelet count, and the incidence of ascites and hepatic encephalopathy among different Child-Pugh grades (all Conclusion: In patients with HCC and splenomegaly, both Child-Pugh and MELD scores can effectively stratify prognosis. However, the MELD score showed superior predictive performance for 1-year survival rate after TACE, which is worthy of more attention in clinical prognosis assessment.

Indexed as

Child-Pugh scorehepatocellular carcinomamodel for end-stage liver diseaseprognosissplenomegalytransarterial chemoembolization

Identifiers

PMID42359075
PMCPMC13290625

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.